Clinical trials located in

Gillingham

Gillingham city is located in United Kingdom. Currently, 6 clinical trials are being conducted in this city.

Gillingham, located in Kent, England, is a historic town with roots stretching back to the Roman era. It became notable in the Middle Ages for its military and naval connections, a legacy that continues with the Royal Engineers Museum showcasing military engineering feats. The town’s strategic location by the River Medway has shaped its development. Gillingham also boasts natural beauty, with Riverside Country Park offering scenic walks. Its rich history is complemented by modern amenities, making it a unique blend of past and present.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Evaluation of the effectiveness of combined therapy in the treatment of bladder cancer with muscle invasion

    This clinical study, known as the VOLGA trial, is for bladder cancer patients who cannot or refuse to take Cisplatin. Two new therapy combinations are being tested. The first combines Durvalumab, Tremelimumab, and Enfortumab Vedotin. The second partners Durvalumab with Enfortumab Vedotin only. Patients receive these drugs both before and after having bladder surgery. This study wants to involve about 830 patients and will assign them blindly to the therapy combinations. Patients will receive the blend for three cycles, with more Durvalumab treatments after surgery. We want to track if the cancer is eradicated after surgery, when the cancer appears again, the survival rate, unwanted effects, and the patients’ well-being. Taking part in this study might require commitment for approximately 3-5 years, with follow-ups to monitor the patient’s progress.

    • Enfortumab vedotin
    • Tremelimumab
    • Durvalumab
  • Evaluation of the effect of ixabepilone in advanced breast cancer

    A clinical study is evaluating the effects of a drug named ixabepilone on advanced breast cancer after other common treatments haven’t worked. The study involves 60 people receiving the drug through an infusion every three weeks. Researchers will look at how well the cancer responds to the treatment, including how long participants live without their cancer getting worse and the overall survival rate. The study is for adults with certain types of advanced breast cancer and will not include healthy volunteers.

    • Ixabepilone
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in United Kingdom:

.